Apellis Pharmaceuticals Inc [NASDAQ: APLS] gained 17.58% on the last trading session, reaching $22.34 price per share at the time.
Apellis Pharmaceuticals Inc represents 125.66 million in outstanding shares, while the company has a total market value of $2.81 billion with the latest information. APLS stock price has been found in the range of $20.445 to $23.56.
If compared to the average trading volume of 2.49M shares, APLS reached a trading volume of 6999039 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Apellis Pharmaceuticals Inc [APLS]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for APLS shares is $36.35 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on APLS stock is a recommendation set at 1.91. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Raymond James have made an estimate for Apellis Pharmaceuticals Inc shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on May 09, 2025. The new note on the price target was released on May 09, 2025, representing the official price target for Apellis Pharmaceuticals Inc stock. Previously, the target price had yet another raise to $44, while Cantor Fitzgerald analysts kept a Overweight rating on APLS stock.
The Price to Book ratio for the last quarter was 17.09, with the Price to Cash per share for the same quarter was set at 2.86.
Trading performance analysis for APLS stock
Apellis Pharmaceuticals Inc [APLS] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 11.20. With this latest performance, APLS shares gained by 25.01% in over the last four-week period, additionally sinking by -24.19% over the last 6 months – not to mention a drop of -29.99% in the past year of trading.
Apellis Pharmaceuticals Inc [APLS]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and Apellis Pharmaceuticals Inc [APLS] shares currently have an operating margin of -24.00% and a Gross Margin at 82.83%. Apellis Pharmaceuticals Inc’s Net Margin is presently recorded at -28.83%.
Apellis Pharmaceuticals Inc (APLS) Capital Structure & Debt Analysis
According to recent financial data for Apellis Pharmaceuticals Inc. ( APLS), the Return on Equity (ROE) stands at -103.82%, highlighting a negative impact on investor capital. The Return on Assets (ROA) is -27.29%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Apellis Pharmaceuticals Inc’s Return on Invested Capital (ROIC) is -35.68%, showcasing its effectiveness in deploying capital for earnings.
Apellis Pharmaceuticals Inc (APLS) Efficiency & Liquidity Metrics
Based on Apellis Pharmaceuticals Inc’s (APLS) latest financial statements, the Debt-to-Equity Ratio is 2.86%, indicating its reliance on debt financing relative to shareholder equity.
Apellis Pharmaceuticals Inc (APLS) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Apellis Pharmaceuticals Inc. (APLS) effectively leverages its workforce, generating an average of -$315042.25 per employee. The company’s liquidity position is robust, with a Current Ratio of 4.08% and a Quick Ratio of 3.62%, indicating strong ability to cover short-term liabilities.
An analysis of Institutional ownership at Apellis Pharmaceuticals Inc [APLS]
There are presently around $104.59%, or 121.18%% of APLS stock, in the hands of institutional investors. The top three institutional holders of APLS stocks are: WELLINGTON MANAGEMENT GROUP LLP with ownership of 16.39 million shares, which is approximately 13.2269%. ECOR1 CAPITAL, LLC, holding 11.61 million shares of the stock with an approximate value of $$445.26 million in APLS stocks shares; and ECOR1 CAPITAL, LLC, currently with $$426.22 million in APLS stock with ownership which is approximately 8.9675%.
